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Abstract
Powered robotic exoskeletons are an emerging technology of wearable orthoses that can be used as an assistive
device to enable non-ambulatory individuals with spinal cord injury (SCI) to walk, or as a rehabilitation tool to
improve walking ability in ambulatory individuals with SCI. No studies to date have systematically reviewed the
literature on the efficacy of powered exoskeletons on restoring walking function. Our objective was to systematically
review the literature to determine the gait speed attained by individuals with SCI when using a powered exoskeleton
to walk, factors influencing this speed, and characteristics of studies involving a powered exoskeleton (e.g. inclusion
criteria, screening, and training processes). A systematic search in computerized databases was conducted to identify
articles that reported on walking outcomes when using a powered exoskeleton. Individual gait speed data from each
study was extracted. Pearson correlations were performed between gait speed and 1) age, 2) years post-injury, 3) injury
level, and 4) number of training sessions. Fifteen articles met inclusion criteria, 14 of which investigated the powered
exoskeleton as an assistive device for non-ambulatory individuals and one which used it as a training intervention for
ambulatory individuals with SCI. The mean gait speed attained by non-ambulatory participants (n = 84) while wearing a
powered exoskeleton was 0.26 m/s, with the majority having a thoracic-level motor-complete injury. Twelve articles
reported individual data for the non-ambulatory participants, from which a positive correlation was found between
gait speed and 1) age (r = 0.27, 95 % CI 0.02–0.48, p = 0.03, 63 participants), 2) injury level (r = 0.27, 95 % CI 0.02–0.48,
p = 0.03, 63 participants), and 3) training sessions (r = 0.41, 95 % CI 0.16–0.61, p = 0.002, 55 participants). In conclusion,
powered exoskeletons can provide non-ambulatory individuals with thoracic-level motor-complete SCI the ability to
walk at modest speeds. This speed is related to level of injury as well as training time.
Introduction
The inability to walk is arguably one of the most notable
impairments that individuals experience after spinal cord
injury (SCI). Besides leading to physical complications
such as skin breakdown, muscle atrophy, reduced car-
diorespiratory capacity, and pain [1], being unable to
walk also affects psychological well-being and can in-
crease the risk of depression and reduce quality of life
[2]. For these reasons, recovery of walking consistently
ranks among the top priorities related to mobility for
individuals with SCI [3]. Unfortunately, a large propor-
tion of these individuals with complete or incomplete in-
jury have limited, if any, recovery of walking function and
are thus limited to a wheelchair for their mobility [4]. Even
with the use of conventional bracing for ambulation, indi-
viduals with SCI must expend high levels of energy [5, 6]
to achieve modest, non-functional gait speeds [6, 7],
dependent on their level of injury [6].
Recent developments in gait orthoses have produced
the powered robotic exoskeleton, a rechargeable bi-
onic device worn over the lower extremities with mo-
torized joints that can provide externally-powered gait
independent of a treadmill system [8]. Compared to
treadmill-based gait orthoses such as the Lokomat
(Hocoma, Switzerland) and LOPES (University of Twente,
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Netherlands), these powered robotic exoskeletons are
compact, lightweight, and portable [9]. This new tech-
nology has been designed as an assistive device to
provide individuals with complete paralysis the ability
to stand and walk independently over-ground in a
natural, full weight-bearing, reciprocal pattern. They
can also be used in the rehabilitation setting as a
training tool to improve stepping and weight-shifting
for ambulatory individuals with SCI [9]. Various de-
signs have been developed, several of which are com-
mercially available and are in the process of being
approved for use at home and in the community. As
with any form of gait rehabilitation, walking with a
powered exoskeleton requires specialized training and
practice.
As a newly developed technology, the current evi-
dence base surrounding the use of powered robotic
exoskeletons in SCI rehabilitation consists of a num-
ber of studies, but the majority are case studies
(single-subject reports) or single-intervention trials
with a small number of participants. A recent system-
atic review found that energy consumption was reduced
when walking with powered orthoses compared to con-
ventional orthoses in paraplegic SCI [10]. A literature re-
view by the same author found that powered gait orthoses
have a beneficial effect on the kinematics and temporal-
spatial parameters of gait, but reported minimally on gait
speed [11]. To our knowledge, no systematic reviews have
specifically determined the gait speed attained by non-
ambulatory individuals with SCI while using a powered
robotic exoskeleton to walk. We defined non-ambulatory
individuals with SCI as those who do not walk regularly,
independently, with or without gait aids or bracing. Gait
speed is an important indicator and will contribute to the
utility of the device; very slow speeds may relegate the de-
vice to uses solely for exercise, while faster speeds may en-
able community ambulation.
The primary objective of this article was to examine
the evidence on the ability of powered robotic exoskele-
tons to provide gait, specifically focusing on gait speed,
in individuals with SCI by performing a systematic re-
view of relevant clinical studies. To provide continuity
across the studies and address the heterogeneity of the
presentation of individuals with SCI, we collected indi-
vidual participant data from each study to explore corre-
lations between participant characteristics and gait
speed. We hypothesized that gait speed would be posi-
tively correlated with spinal cord preservation (lesion
level), as well as training time. Before acquiring a pow-
ered robotic exoskeleton, clinicians and users alike
should have an understanding of the feasibility of pow-
ered exoskeleton use. Thus, secondary objectives were to
summarize the (1) screening process for determining
suitability for an exoskeleton and the (2) training process




We conducted this systematic review according to the
PRISMA guidelines and the review protocol is available
from the authors [12]. We accessed MEDLINE (1946 to
May 6, 2015), EMBASE (1980 to May 6, 2015), Cochrane
Central Register of Controlled Trials (1991 to May 6,
2015), and CINAHL (1982 to May 6, 2015). An electronic
database search was first conducted using the terms
“spinal cord injury” OR “SCI” OR “quadriplegia” OR
“tetraplegia” OR “paraplegia” paired using AND with
“walk” OR “walking” OR “gait” OR “ambulation”. The
search results were then paired using AND with “exoskel-
eton” OR “exoskeletal” OR “powered gait orthosis” OR
“PGO” OR “ReWalk” OR “Ekso” OR “indego” OR “hybrid
assistive limb” OR “HAL”. English language and human
studies were used as restrictions. Hand searches of refer-
ence lists from retrieved articles were completed. Titles,
abstracts, and full-texts were screened by two independent
reviewers; only studies that met inclusion criteria were se-
lected and used for further analysis.
Eligibility criteria were studies that evaluated walking
outcomes of individuals with SCI after training with a
powered robotic exoskeleton. We defined powered exo-
skeleton as a multi-joint orthosis that uses an external
power source to move at least two joints on each leg,
which is portable, and can be used independent of a
treadmill or body-weight support. Papers were selected
if they reported gait speed by use of relevant over-ground
walking tests (e.g. 10-Meter Walk Test) or temporal-
spatial measures relevant to walking (step length, dis-
tance, time walking). Additional inclusion criteria were:
(1) adult patients over 18 years of age; and (2) peer-
reviewed full articles published or “in press”. Exclusion
criteria were studies that only utilized a combination of
functional electrical stimulation (FES) with the exoskel-
eton (hybrid exoskeleton), studies that only reported
joint angle and muscle moments, or studies that utilized
populations with mixed diagnoses (e.g. SCI and stroke)
and did not separate the results. Abstracts and confer-
ence posters were excluded, as were studies that utilized
an orthosis powered only at one joint or a treadmill for
testing.
Design characteristics, inclusion and exclusion criteria,
sample demographics, exoskeleton characteristics, train-
ing protocol, and adverse events were extracted from
each study. Individual participant demographics and
walking data were extracted from studies, when avail-
able, and compiled for statistical analysis. Gait speed was
calculated, when not directly reported, from walking
outcomes such as the 10-Meter Walk Test (10MWT) or
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other timed measure. We used the Pearson product-
moment correlation coefficient to determine relation-
ships between common participant variables available
from the studies (age, years post-injury, injury level,
number training sessions) and independent gait speed
(hence, without assistance) while walking within the exo-
skeleton device. We omitted individuals with motor-
incomplete injuries from these calculations due to the
heterogeneous presentation of incomplete SCI. Injury
level was coded as 0 to 17, representing C4 to L1.
Results
As illustrated in Fig. 1, our search results yielded 145 re-
cords across the MEDLINE, CINAHL, EMBASE, and
Cochrane databases. After screening for eligibility, 15 ar-
ticles [13–27] were included in this review (Table 1);
seven eligible records were excluded from the final
count due to overlapping of participant data. All but two
records [14, 24] provided individual participant data that
could be extracted for statistical analysis.
Study design
The 15 studies ranged from single-subject case studies to
prospective intervention trials comparing other types of
orthoses within the study. Thirteen studies [14, 16–27]
used the powered exoskeleton as an assistive device for
ambulation, and thus were post-test studies; in these
studies, outcomes were only measured while wearing
the device, after a period of training, since individuals
did not have the ability to walk without the device
(mostly participants with complete injuries). One study
[13] used the powered exoskeleton as a training inter-
vention to improve ambulation, assessing walking with-
out the device in a pre-post study design in participants
with incomplete and low-complete ambulatory SCI.
One study [15] used the powered exoskeleton as both
an assistive device as well as training intervention, as
they included motor complete and ambulatory incom-
plete SCI. No studies included a control group and all
participants received the powered exoskeleton as their
intervention. Two studies [14, 18] compared a powered
exoskeleton to standard rigid orthoses, where the same
participants trialed multiple orthoses.
Exoskeletons
Of the 15 studies included, 12 studies [13, 15–23, 26, 27]
used commercially developed exoskeletons, such as
the ReWalk (ReWalk Robotics, Israel), Ekso (Ekso
Bionics, USA), and the Indego (Parker Hannifin Cor-
poration, USA). Two studies investigated exoskeletons
developed for research purposes: the Wearable Power
Assist Locomotor (WPAL) [25] and Mina [24]. One
study [14] utilized a custom device designed by the
authors in a previous study [28], an isocentric recipro-
cating gait orthosis (IRGO) combined with electrically
actuated motors. All exoskeletons in the included
studies were actuated at the hip and knee joints. The
control of walking while wearing a powered exoskel-
eton varies, with some exoskeletons having multiple
control options (Table 2).
Fig. 1 Study results during PRISMA phases: a flowchart of selection process based on inclusion/exclusion criteria
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Inclusion/exclusion criteria
Ten of the 14 studies using the powered exoskeleton as an
assistive device for non-ambulatory individuals with SCI
included motor complete or complete SCI (AIS A/B),
while three [15, 20, 26] included incomplete SCI (AIS C).
One study [22] allowed any participant with lower extrem-
ity weakness or paralysis to be eligible, and provided SCI-
specific data. Seven studies [15–17, 20, 22, 26, 27]
allowed cervical-level injuries to be eligible; the rest
of the studies either listed thoracic-level injury or
below T1 to qualify for the inclusion criteria. Thir-
teen studies [13, 15–23, 25–27] specified height and
weight restrictions, generally within the range of 1.45 m to
2.0 m and less than 113 kg. Time post-injury for inclusion
varied as well, when mentioned, with one study [21] set-
ting a maximum time of two years post-injury, and five
studies setting a minimum time post-injury of six months
[16, 26, 27] or one year [15, 23]. Three studies [16, 24, 27]
required participants to be a regular RGO user in order to
be included, and two [15, 22] required participants to be
able to maintain an upright posture with or without a
standing device.
The study [13] using the powered exoskeleton solely
as a training tool for ambulatory individuals included
only those with traumatic SCI to the conus medullaris/
cauda equina with chronic incomplete or complete
Table 1 Characteristics of studies included in the review





Aach et al. (2014) [13] HAL Training tool 8 (AIS A to D, T8 to L2) 6MWT, 10MWT, TUG 5d/wk for 90 days,
90 min per session
Arazpour et al. (2013) [14] Custom powered
IRGO
Assistive device 5 (AIS A/B, T6 to T12) Gait speed, distance 3d/wk for 8 weeks,
2 h per session
Benson et al. (2015) [15] ReWalk Assistive device/
Training Tool
5 (AIS A/C), C7 to L1 6MWT, 10MWT, TUG 2d/wk for 10 weeks,
2 h per session
Esquenazi et al. (2012) [16] ReWalk Assistive device 12 (AIS A/B, T3 to T12) 6MWT, 10MWT 3d/wk for 8 weeks,
75–90 min per session
Evans et al. (2015) [17] Indego Assistive device 5 (AIS A, T6 to T12) 6MWT (self-selected
pace, fast pace)
At least 5 sessions
Farris et al. (2014) [18] Indego Assistive device 1 (AIS A, T10) 6MWT, 10MWT, TUG 20 sessions in one year
Fineberg et al. (2013) [19] ReWalk Assistive device 6 (AIS A/B, T1 to T11) Gait speed 3d/wk for up to 6 months,
1–2 h per session
Hartigan et al. (2015) [20] Indego Assistive device 16 (AIS A to C, C5 to L1) 6MWT, 10MWT 5 sessions,
90 min per session
Kolakowsky-Hayner et al.
(2013) [21]
Ekso Assistive device 7 (AIS A, T4 to T12) Walking distance, time 6d/wk for 1 week,
up to 60 min per session
Kozlowski et al. (2015) [22] Ekso Assistive Device 7 (AIS A to C, C4 to L1) 2MWT, longest walk Up to 24 sessions, up to
2 h per session
Kressler et al. (2013) [23] Ekso Assistive device 3 (AIS A, T1/2 to T9/10) Gait speed, distance 3d/wk for 6 weeks,
60 min per session
Neuhaus et al. (2011) [24] Mina Assistive device 2 (AIS A, T10 and T12) Gait speed 9 sessions
Tanabe et al. (2013) [25] WPAL Assistive device 7 (AIS A/B, T6 to T12) Walking distance, time 2–11 sessions,
60 min per session
Yang et al. (2015) [26] ReWalk Assistive Device 12 (AIS A to C, C8 to T11) 6MWT, 10MWT Up to 102 sessions,
1–2 h per session
Zeilig et al. (2012) [27] ReWalk Assistive device 6 (AIS A/B, T5 to T12) 6MWT, 10MWT, TUG Until able to walk
100 m unassisted
HAL Hybrid Assistive Limb; 6MWT Six Minute Walk Test; 10MWT Ten Meter Walk Test; TUG Timed Up and Go Test; IRGO Isocentric Reciprocal Gait Orthosis; 2MWT
Two Meter Walk Test; WPAL Wearable Power-Assist Locomotor
Table 2 Control options to initiate stepping for powered
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HAL Hybrid Assistive Limb, WPAL Wearable Power-Assist Locomotor,
IRGO Isocentric Reciprocal Gait Orthosis
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paraplegia with extensive zones of partial preservation.
Regardless of completeness, they required participants to
have some volitional motor function of the hip and knee
extensor and flexor groups in order to use the Hybrid
Assistive Limb (HAL) exoskeleton (Cyberdyne, Japan),
which detects the user’s bioelectrical signals to generate
stepping.
Of all the studies included in this review, 11 of the
studies had stated exclusion criteria. The exclusion cri-
teria generally consisted of severe comorbidities that
would make it unsafe for the participant to use the pow-
ered exoskeleton: concurrent neurological or other pro-
gressive disease [14–16, 21, 25–27]; unstable spine,
fracture risk or osteoporosis [13, 15–17, 21–23, 25–27];
cardiorespiratory limitations to exercise such as auto-
nomic dysreflexia [13, 16, 17, 21–23, 25, 26]; pressure
sores at point of contact [13, 16, 17, 21–23, 25–27]; se-
vere limitations in range of motion due to contracture,
heterotypic ossification, or spasticity [13–17, 21–23, 25, 26];
or cognitive deficits [13, 15, 16, 21, 25, 27]. Other exclu-
sion criteria were pregnancy [17, 21, 23], asymmetric hip
positions [14, 23], surgery in the last three months [23],
participation in lower extremity conditioning in last three
months [23], previous use of any robotic exoskeletal de-
vice [15], Type I or II Diabetes [23], and pain limiting fore-
arm crutch use [23]. Only one study [13] listed non-
traumatic SCI as an exclusion criteria for their study.
Powered exoskeleton as an assistive device for ambulation
Participants and level of impairment
There were 92 participants (74 males) across the 14
studies that utilized a powered exoskeleton as an assist-
ive device for ambulation. Of these participants, the ma-
jority were motor complete (AIS A or B) thoracic-level
SCI (Table 1); six participants had incomplete SCI. The
highest level of injury included was C4 and the lowest
was L1 with a mean injury level of T7. Participants
ranged from two months post-injury to 24 years, with a
mean of 5.8 years (SD: 5.6 years) after injury. The mean
age of participants across all studies was 37.5 years (SD:
12.3 years).
Gait speed
Of the 14 studies utilizing the powered exoskeleton as an
assistive device, eight studies [15, 16, 18–20, 23, 26, 27]
assessed gait speed by means of the 10MWT, while two
studies [14, 24] simply reported gait speed. Two studies
[21, 25] reported walking parameters (time and distance)
recorded during a session that could be used to calculate a
gait speed; these session durations were generally quite
long, ranging from 4.5 to 54 min. Two studies [17, 22] cal-
culated gait speed from measures of endurance: the 2-
Minute Walk Test (2MWT) and 6-Minute Walk Test
(6MWT). Twelve studies reported individual participant
gait speed, which ranged ranged from 0.031 m/s to
0.71 m/s. The mean gait speed attained by the 84 partici-
pants in these 12 studies was 0.26 m/s (SD: 0.15 m/s)
(Table 3).
Gait aid at assessment
At this time, powered exoskeletons require the use of a
gait aid for support during stepping. The general expect-
ation is for exoskeleton users to eventually progress to
forearm crutches, which provide less stability than walk-
ing frames but are less bulky and thus more portable.
One study [20] which included individuals with cervical-
level SCI, allowed participants to use a platform walker
if needed. Seven studies [14, 17, 18, 20, 21, 23, 26]
allowed participants to use a 2-wheeled walker for as-
sessment; 10 studies [15–17, 19–22, 24, 26, 27] had par-
ticipants who achieved exoskeletal walking with forearm
crutches by the end of the training period.
Control of exoskeleton and independence
The control of walking while wearing a powered exo-
skeleton varies (Table 2). In two studies [23, 25], partici-
pants ambulated by controlling stepping with buttons on
their walker. In 10 studies [15–20, 22, 23, 26, 27], partic-
ipants generated stepping by shifting their own weight
within the exoskeleton; the exoskeleton is able to detect
changes in centre of mass over one limb and in response
generates a step contralaterally. In another three studies
[14, 21, 24], exoskeletal stepping was initiated by an exter-
nal operator using a control interface. While all studies re-
ported on participants that did not require assistance, four
studies [19, 20, 22, 26] also reported on several partici-
pants requiring minimal to moderate hands-on assistance
with the exoskeleton during the gait assessment. The
Table 3 Mean gait speed of non-ambulatory participants while
using exoskeleton at end of training period
Gait speed (m/s)
Mean (SD)
Participants with individual data (n = 84) 0.26 (0.15)
Incomplete SCI participants (n = 6) 0.32 (0.25)
Complete SCI participants (n = 78) 0.25 (0.14)
By device
ReWalk (n = 37) 0.28 (0.15)
Ekso (n = 18) 0.14 (0.07)
Indego (n = 20) 0.31 (0.11)
WPAL (n = 7) 0.16 (0.06)
By assistancea
No hands-on assistance (n = 63) 0.26 (0.15)
Hands-on assistance (n = 15) 0.21 (0.07)
SD Standard Deviation, WPAL Wearable Power-Assist Locomotor
aHands-on physical assistance provided during evaluation of gait speed
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mean gait speeds attained by participants using the exo-
skeleton as an assistive device, grouped by exoskeleton,
level of assistance, and completeness of injury, are shown
in Table 3.
Training protocol
As seen in Table 1, training period varied significantly
across the studies included in this review. Some studies in-
volved a shorter training period [17, 20, 21, 24, 25, 27],
often ending when the exoskeleton user achieved inde-
pendence or the ability to walk a set distance; other stud-
ies [14–16, 19, 22, 23] utilized a set training protocol
lasting several weeks to months, not based on participant
progress. One study [26] did not have a set training proto-
col or end-point, with participants undergoing between 12
and 102 training sessions to achieve their best perform-
ance with the exoskeleton. An aggregate mean of 19.8
(SD = 18.6, n = 79) training sessions was calculated across
all studies; training sessions were 60 to 120 min in dur-
ation. In all studies, participants were generally progressed
from standing in the exoskeleton to weight shifting and
stepping exercises to walking either within parallel bars or
using a gait aid. In three studies [15, 19, 22], participants
were progressed to training on different surfaces including
sidewalk, grass, or stairs. Tanabe et al. [25] incorporated a
treadmill as part of the training protocol to improve user
confidence and speed. Only one study included upper ex-
tremity strengthening and lower extremity stretching as
part of the intervention protocol [14].
Powered exoskeleton as a training tool to improve
ambulation
As an intervention for ambulatory individuals with SCI,
eight participants trained with the HAL in the Aach et
al. [13] study for five days a week over a 90-day period
(mean of 51.75 sessions). Participants ambulated on a
body weight-supported treadmill while wearing the HAL;
speed and body weight-support were adjusted individually.
At the end of the intervention period, the participants im-
proved their mean gait speed without the exoskeleton
from 0.28 m/s to 0.50 m/s (p < 0.05, n = 8, effect size =
0.71). They also demonstrated an improvement in mean
6MWT distance from 70.1 m to 163.3 m (p < 0.05, n = 8,
effect size = 0.64). On the other hand, the two participants
with incomplete SCI in the Benson et al. [15] study did
not show clear improvements in mean gait speed (0.26 m/s
to 0.27 m/s) or 6MWT distance. In contrast to the Aach
et al. [13] study, these two participants underwent only 20
training sessions over 10 weeks, which did not include
continuous treadmill training.
Adverse events
Across all 15 articles, five [14, 17–19, 25] did not report
on whether any adverse events occurred with use of a
powered exoskeleton. Of the 10 studies that reported on
adverse events, five [13, 22–24, 27] reported no skin
changes, while five [15, 16, 20, 21, 26] reported mild skin
effects (redness or superficial abrasions). Four articles
[16, 21, 23, 24] addressed and reported no change in
spasticity, and five [16, 21, 23, 24, 27] which addressed
pain reported no change or a slight decrease in usual
pain. Safety precautions, such as overhead tether or
close guarding, were taken in all studies to ensure par-
ticipant safety, though loss of balance was used for some
articles as an outcome measure. In one study [21], falls
engaging the overhead tether were reported for three
participants over six days of training; two of these partic-
ipants experienced a combined three falls due to mech-
anical programming errors of the exoskeleton, while the
third participant experienced over 10 falls due to mal-
functioning of specialized forearm crutches which were
later discontinued. Two studies [16, 24] reported some
lower extremity edema due to prolonged standing. One
study [15] removed a participant for safety reasons due
to a “near-serious” device-related adverse event involving
a hairline fracture of the talus that did not require
treatment.
Factors influencing exoskeletal gait speed in non-ambulatory
individuals with SCI
Four variables were found in the majority of studies which
might influence gait speed in non-ambulatory individuals
using the exoskeleton device to walk: age, injury duration,
injury level, and number of training sessions. As the num-
ber of incomplete participants across all the studies was
small (n = 6), they were not included in the correlational
analyses. We also removed the participants who required
hands-on assistance to ambulate with the exoskeleton
from the correlation calculations.
All 12 studies reporting individual data provided infor-
mation on participant age; in some cases, a narrow age
range (e.g. 20–24) was provided, and the midpoint of the
range was used for that individual. A significant correl-
ation was found between increasing age and faster gait
speed (r = 0.27, 95 % CI 0.02–0.48, p = 0.03, n = 63)
(Fig. 2). However, no relationship was found between
injury duration and gait speed (r = 0.19, 95 % CI −0.09–
0.44, p = 0.18, n = 53) from 10 studies. From the 12 stud-
ies, we found a significant correlation between injury
level and gait speed (r = 0.27, 95 % CI 0.02–0.48, p =
0.03, n = 63). Higher speeds were associated with a lower
level of injury when walking with an exoskeleton as an
assistive device (Fig. 3).
Eleven studies reported the number of training ses-
sions for individual participants. Those who were able to
practice longer with the powered exoskeleton achieved
faster gait speeds (r = 0.27, 95 % CI 0.003–0.49, p = 0.048,
n = 56). One individual in the Yang et al. [26] study
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underwent 102 training sessions to achieve their best
walking outcome, compared to the group mean of 19.8
sessions. When we removed this outlier, the correlation
coefficient increased to 0.41 (95 % CI 0.16–0.61; p = 0.002,
n = 55) (Fig. 4).
Discussion
The advent of the powered exoskeleton in rehabilitation
has many implications for individuals with SCI with lim-
ited or no walking ability. It allows wheelchair-users to
stand and ambulate, which may influence community
mobility and social participation. Powered exoskeletons
also require less energy to use than standard rigid orth-
oses [10] and are becoming lighter and more accessible.
Use of powered exoskeletons without overhead body-
weight support for over-ground ambulation is a new re-
habilitation strategy, and to our knowledge our review is
the first to examine their ability for promoting gait speed
for individuals with SCI.
The relationship between level of injury and gait speed
suggests that proficiency of powered exoskeletal walking
is linked to the functional presentation of the user. Indi-
viduals with more neurological preservation of their
spinal cord are more likely to achieve greater speeds
Fig. 2 Gait speed plotted against age using individual participant data, excluding those with incomplete injuries or requiring assistance to
ambulate (n = 63 from 12 studies)
Fig. 3 Gait speed plotted against injury level using individual participant data, excluding those with incomplete injuries or requiring assistance to
ambulate (n = 63 from 12 studies)
Louie et al. Journal of NeuroEngineering and Rehabilitation  (2015) 12:82 Page 7 of 10
with a powered exoskeleton. Though the upper extrem-
ities are considered spared in all thoracic-level SCI, indi-
viduals with high thoracic injuries include pectoralis
major and latissimus dorsi in their postural control
muscle synergies [29]; individuals with greater preserva-
tion have more trunk musculature activation and can
control their centre of mass with less dependence on
the arms. Currently, all powered exoskeletons require
the use of an additional gait aid, and some generate
stepping in response to lateral shifts of centre of mass.
An individual with less reliance on the upper extremities
for maintaining postural stability will be more able to lift
or push their gait aid and to navigate their centre of
mass.
There was an unexpected relationship found between
age and gait speed, with older participants achieving
greater speeds than younger participants. One possible
explanation for this relationship may lie in the epidemi-
ology of SCI. Younger individuals with SCI tend to sus-
tain a traumatic SCI, while older individuals with SCI
tend to have a non-traumatic SCI [30, 31]. Further to
this, traumatic SCI tends to result in a higher level of in-
jury and more neurological impairment than non-
traumatic SCI [32, 33]. Many of the studies included in
this review did not indicate whether participants had a
traumatic or non-traumatic injury, so we could not con-
firm this hypothesis. However, a post-hoc analysis found
a non-significant trend between increasing age and lower
levels of injury (i.e. less neurological impairment) (r =
0.20, 95 % CI −0.05–0.43, p = 0.11, n = 63). Without con-
trolling for injury level, we would then expect the older
individuals in our included studies to walk faster than
younger individuals.
Participants were able to ambulate independently within
a reasonable training time, with some subjects doing so
within the first training session. However, those who
were able to train for several weeks to months were
generally able to achieve ambulation at faster speeds
with a powered exoskeleton. Repetitive task practice is
a requirement for improved speed and accuracy of a
new skill [34], and is a possible explanation for this re-
lationship. As exoskeletons are beginning to be ap-
proved for personal and home use, daily use may help
exoskeleton-users attain higher gait speeds quickly.
Our findings showed that use of a powered exoskeleton
allowed non-ambulatory individuals with SCI to ambulate
at a mean speed of 0.26 m/s, despite the maximum speed
of commercial powered exoskeletons such as the ReWalk
being 0.55 m/s (ReWalk™ Personal System User Guide,
ReWalk Robotics, Israel). A gait speed of 0.26 m/s is not
considered sufficient for community ambulation; Forrest
et al. [35] found a threshold of 0.44 m/s for limited com-
munity ambulation after incomplete SCI while Andrews
et al. [36] determined the mean speed necessary to cross
an intersection as set by traffic signals to be 0.49 m/s.
However, 0.26 m/s is within a range comparable to indi-
viduals with incomplete SCI who are able to walk with or
without supervision indoors [37]. In our included studies,
one individual with a motor-incomplete C8 SCI using a
ReWalk was able to ambulate at 0.71 m/s, higher than the
device’s reported maximum speed of 0.55 m/s.
As a training intervention for ambulatory individuals
with SCI, participants in the Aach et al. [13] study dem-
onstrated significant improvements in gait speed and en-
durance with use of a powered exoskeleton. These large
improvements may be due in part to the principles of
Fig. 4 Gait speed plotted against number of training sessions using individual participant data, excluding those with incomplete injuries or
requiring assistance to ambulate (n = 55 from 11 studies, one outlier removed)
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motor learning and neuroplasticity. The high level of
repetition on the treadmill and feedback of successful
active stepping with combined use of the bioelectric
signal-dependent HAL exoskeleton may have helped to
strengthen the intact neural pathways in incomplete SCI
[38]. On the other hand, the two participants in the
Benson et al. [15] study with incomplete SCI did not
show any improvement in gait speed or endurance. Simi-
larly, a systematic review of treadmill-based robotics-
assisted locomotor training found reduced walking
endurance and no difference in gait speed after robotics-
assisted locomotor training using the Lokomat (Hocoma,
Switzerland) compared to other forms of gait training
[39]. Due to these mixed findings, further research in this
population is required to investigate the potential of pow-
ered exoskeletons as a training tool.
The training protocol was similar across all the stud-
ies, progressing from becoming familiar with standing
and balancing in the exoskeleton to stepping and walk-
ing within the exoskeleton. This progression of confi-
dence is similar to training with other lower limb
orthoses, with repetition being a key principle for train-
ing. All studies employed safety precautions (spotting
and overhead tether) to ensure safety and confidence
while learning to use a new assistive device.
This systematic review has some limitations. The level
of evidence in the current literature is limited to studies
with a small number of participants. In addition, a true
control group (without a device to walk) is not relevant
as most participants would not have been able to walk
without the exoskeleton; however, future studies could
compare different orthotic, FES, or exoskeleton systems.
There was heterogeneity in the study characteristics (de-
vice, control of stepping, training duration, outcome
measurement), which made it challenging to compare
results and reduces the ability to generalize results.
However, we attempted to overcome this by aggregating
participant data to allow statistical analysis to explore
correlations between participant characteristics and out-
comes. In the future, it would be useful for studies to re-
port on the exact intensity of training, using such
measures as number of steps or walking time.
Conclusion
In conclusion, powered exoskeletons can provide individuals
with thoracic-level motor-complete SCI the ability to walk
at modest speeds. Exoskeletal gait speed is related to the
amount of time spent practicing as well as level of injury.
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